Sensus Healthcare (NASDAQ:SRTS) is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls. These systems allow dermatologists and radiation oncologists to administer precise doses of radiation directly to lesions while sparing surrounding healthy tissue. In addition to its hardware, Sensus Healthcare offers training, credentialing support and treatment planning assistance, helping clinics and hospitals integrate SRT into their service offerings and meet regulatory requirements.
Founded in 2004 and headquartered in Jacksonville, Florida, Sensus Healthcare has built a network of clinical partners and distributors across the United States and select international markets. The company’s sales and service organization works closely with dermatology practices, oncology centers and academic institutions to facilitate device installation, maintenance and ongoing technical support. Over time, Sensus Healthcare has expanded its outreach through strategic collaborations with key opinion leaders and specialty societies to raise awareness of superficial radiation therapy protocols and best practices.
Under the leadership of President and CEO R. Scott Ruskin, Sensus Healthcare continues to pursue research and development initiatives aimed at broadening the clinical applications of its SRT technology. The company remains focused on generating long-term data on treatment efficacy and patient outcomes, while exploring opportunities to enhance device capabilities and workflow integration. With a growing installed base and a commitment to education and clinical validation, Sensus Healthcare positions itself as a dedicated provider of non-invasive radiation therapy solutions for dermatology and oncology practitioners.
